Vitamin E (tocopherol) veterinary grade active pharmaceutical ingredient is supplied as a lipophilic redox-active chromanol derivative used directly in oral tablets, hard-gelatin capsules, injectable emulsions, dry powders, granules, feed premixes and aqueous micellar solutions. The API class includes free RRR-α-tocopherol, all-rac-α-tocopherol, α-tocopheryl acetate, α-tocopheryl hydrogen succinate and tocopheryl polyethylene glycol succinate. The acetate and succinate esters are preferred where oxidative stability during high-shear granulation or terminal sterilization is required. CAS registration separates the main commercial forms: 59-02-9 for α-tocopherol, 7695-91-2 for all-rac-α-tocopheryl acetate and 58-95-7 for RRR-α-tocopheryl acetate. A veterinary-grade designation is not a single pharmacopoeial monograph but a release-and-control profile aligned to Ph. Eur., USP and VICH GL18 residual-solvent requirements. The material is tested against microbial enumeration, bacterial endotoxin, peroxide value and elemental impurity limits that are frequently tighter than feed-additive grades. The API is handled as a high-viscosity oil, a low-melting waxy ester, or a silica-adsorbed free-flowing powder depending on downstream dosage form. Free tocopherol functions as a stoichiometric peroxyl-radical scavenger; esterified forms are carrier-stable but require in vivo hydrolysis to release the chromanol active. Principal supply forms include ≥ 50% total tocopherol adsorbates, ≥ 96% ester oils, and spray-dried powders at 50–75% activity for direct compression. Residual surface oil on a powder above 3.0% w/w can impede tablet compression and cause sticking on 24-station rotary presses. VICH GL18 and Ph. Eur. 2.4.24 identity testing are common release anchors; in injectable applications, USP <85> endotoxin limits are binding.

What Release Limits Distinguish a Veterinary Parenteral-Grade Tocopherol from a Feed-Premix Oil?

The release profile for a veterinary parenteral-grade tocopherol API is more restrictive than a feed-premix oil, particularly for bacterial endotoxin, peroxide value, residual solvents and elemental impurities. Feed-grade mixed tocopherol concentrates may be released solely on total tocopherol content and heavy-metal screening, while a veterinary API requires identity, assay, related substances, residual solvent and microbial controls. The table below lists representative acceptance criteria for an α-tocopheryl acetate veterinary API intended for injectable and oral-solid multipurpose use; limits for oral premix material may differ upward for endotoxin and microbial count.

The endotoxin threshold of ≤ 0.5 EU/mg is not required for oral powders, granules or premixes unless the same lot is designated for parenteral conversion. When a single API lot is intended for both oral and injectable use, the parenteral limit governs release and the certificate of analysis must demonstrate compliance with the lower limit. Peroxide value is less informative for acetate esters because the phenolic hydroxyl is blocked; stability-indicating assay of free tocopherol content is therefore used to measure de-esterification during storage. Residual solvent limits follow VICH GL18 for veterinary medicinal products and are not automatically identical to ICH Q3C limits for human pharmaceuticals, although in practice methanol and ethyl acetate Class 3 controls overlap.

In comparison with feed-grade mixed tocopherol concentrates, the veterinary API is distinguished by assay specificity and by control of oxidative degradation products. Feed-grade oils often contain mixed α-, β-, γ- and δ-tocopherol isomers with variable biological activity; a veterinary API intended for tablets or injections requires a single-marker assay traceable to RRR-α-tocopherol or all-rac-α-tocopheryl acetate reference material. The synthetic all-rac form contains eight stereoisomers; RRR-α-tocopherol is the single naturally occurring stereoisomer. Historically assigned biopotency values are 1.49 IU/mg for RRR-α-tocopherol, 1.36 IU/mg for RRR-α-tocopheryl acetate and 1.00 IU/mg for all-rac-α-tocopheryl acetate. These conversion factors persist in many veterinary monographs and feed calculations even though IU labelling has been largely replaced by milligram active moiety. For injectable emulsions, the free phenolic form is more rapidly active as an antioxidant but is more difficult to sterilize without degradation; the acetate ester is generally selected for oxidative stability and lower viscosity.

High-Shear Granulation and Oil-Loading Limits for Tablet and Premix Intermediates

In high-shear granulation, α-tocopheryl acetate oil is pre-blended with a porous carrier such as colloidal silicon dioxide, calcium silicate or microcrystalline cellulose before addition to the dry blend. Production-scale experience with a 300 L rapid mixer granulator indicates that oil loading above 12% w/w of the total granulation mass can produce coalesced granules with broad particle-size distribution and reduced compaction. The oil phase is typically warmed to 40–50 °C before spraying through a pressure pot and binary nozzle, because viscosity at 20 °C exceeds 1500 mPa·s for high-purity acetate oil and impedes uniform droplet deposition. Binder addition should be staged after oil distribution; adding oil and aqueous binder simultaneously can generate hydrophobic granule clusters and variable hardness. For direct compression of a silica-adsorbed tocopherol acetate powder at 50% activity, a compacting compression profile with 8–12 kN main force on a rotary tablet press is generally sufficient for 300 mg round convex tooling, provided the surface oil is below 3.0% w/w and the lubricant level does not exceed 1.0% w/w magnesium stearate. Pre-drying of the granulation at 40 ± 2 °C to a loss-on-drying below 2.5% is required when relative humidity at the line exceeds 60%, because moisture shifts the hydrophobic powder flow and increases sticking propensity.

For feed premix intermediates, a low-shear ploughshare mixer is used to distribute the adsorbed powder into a mineral or corncob carrier. Segregation risk increases when the carrier bulk density differs by more than 0.2 g/mL from the adsorbed powder. The active content in a 1 kg unit dose premix is generally adjusted to provide the target tocopherol intake after dilution into final feed at 0.5–2.0 kg/t, but the exact addition rate depends on the target animal species and the national veterinary formulation file. Published data for this specific configuration is limited; the blend uniformity must therefore be confirmed by sampling at the beginning, middle and end of the mixer discharge, with acceptance limits set in the registered dossier.

When Injectable Emulsions Require Low-Endotoxin Tocopherol API

Injectable formulations use α-tocopheryl acetate as the oil phase or as a co-solvent in medium-chain triglycerides, emulsified with egg lecithin, polysorbate 80 or glycerol monooleate. The emulsion is processed through a high-pressure homogenizer at 700–1000 bar for 2–4 passes to achieve a median droplet diameter below 200 nm. The API must be low in bacterial endotoxin and low in peroxides because high-shear homogenization in the presence of dissolved oxygen accelerates hydroperoxide formation. The aqueous phase is nitrogen-sparged before mixing, and the finished emulsion is filled under headspace oxygen below 2%. Terminal sterilization at 121 °C for 15 min is preferred only for acetate esters; free tocopherol is more susceptible to thermal oxidation and may produce chroman dimers that increase color and related substances. Iron and copper ions in the aqueous phase must be chelated with disodium edetate at 0.005–0.01% w/w, because trace transition metals reduce the induction period of the oil phase. Inprocess pH is maintained between 6.0 and 7.0 to limit ester hydrolysis during sterilization.

For aqueous oral solutions, tocopheryl polyethylene glycol succinate is dissolved in purified water at 50–60 °C with gentle mixing; high-shear dispersion is not required. The solution is then cooled under a nitrogen blanket and filtered through a 0.45 μm membrane before filling. Polyethylene glycol succinate is incompatible with strong oxidizing agents and may precipitate when the solution ionic strength exceeds 0.15 M sodium chloride. For oil-based oral solutions, free RRR-α-tocopherol or α-tocopheryl acetate is diluted in soybean oil or medium-chain triglycerides to a final concentration of 20–100 mg/mL. Nitrogen blanketing and amber glass or HDPE containers are required because both free tocopherol and acetate are light-sensitive under sustained UV exposure. Capsule filling of acetate oil at 50–200 mg per hard-gelatin capsule requires vacuum degassing of the oil before filling to prevent brittle capsule shells caused by headspace oxygen.

Storage and packing conditions are part of the release specification. Bulk oil is filled into food-grade epoxy-phenolic-lined steel or HDPE drums under nitrogen, with a recommended storage temperature below 25 °C and protection from light. Spray-dried powders are filled into sealed foil-lined LDPE pouches with desiccant when ambient relative humidity exceeds 60%; the desiccant is not a substitute for pre-drying if the powder has already absorbed moisture. The material should not be combined with strong oxidizing agents, peroxygen compounds, or uncoated iron and copper salts. In injectable formulations, terminal sterilization of free tocopherol in the presence of oxygen above 2% is a known degradation boundary and is avoided by selecting the acetate or succinate ester or by adding nitrogen overlay and a lipophilic radical termination agent.